Plain-English translation of NCT02567136 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are trying to find measurable signs—called biomarkers—of ALS and a related condition called Primary Lateral Sclerosis using advanced brain imaging scans. The study will compare brain scans from people with ALS, people with Primary Lateral Sclerosis, and healthy volunteers. Finding these biomarkers could help doctors better understand the disease and develop improved treatments.
Currently, there are no clear biological markers that doctors can use to track ALS disease activity or predict how quickly it will progress. Identifying these markers through brain imaging could lead to better ways to monitor the disease and test new treatments.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will undergo two types of brain MRI scans at a medical center—one standard scan and one more detailed scan—that will take about 75 to 90 minutes total. The study is longitudinal, meaning researchers may follow you over time to track changes in the imaging markers. You will be part of one of two groups: people with ALS or healthy control volunteers.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States
Enrollment target
~30 participants
Started
September 2015
Primary completion
September 2030
Age range
21 Years – 75 Years
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Valerie Ferment
University of Minnesota
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.